Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Cabozantinib offers survival benefits to ICI-treated HCC patients
A phase II trial of cabozantinib demonstrates the study drug’s efficacy in patients with hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitor (ICI) regimens.
Cabozantinib offers survival benefits to ICI-treated HCC patients
11 Aug 2024
CLD status does not influence MACE risk associated with ticagrelor vs clopidogrel
Use of ticagrelor compared with clopidogrel contributes to a similar risk of major adverse cardiovascular events (MACE) and a higher risk of major bleeding in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), reveals a study.
CLD status does not influence MACE risk associated with ticagrelor vs clopidogrel
01 Aug 2024
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
Evaluation and treatment rates of patients with chronic hepatitis B (CHB) remain poor worldwide and differ by sex and race or ethnicity, reports a real-world study.
Sex, ethnic disparities affect evaluation, treatment rates of CHB patients
19 Jul 2024
Glecaprevir/pibrentasvir shows favourable efficacy signals for paediatric HCV
Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.
